Cerevel Therapeutics Holdings, Inc. (CERE)
Market Cap | 7.67B |
Revenue (ttm) | n/a |
Net Income (ttm) | -432.84M |
Shares Out | 181.58M |
EPS (ttm) | -2.67 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 920,383 |
Open | 42.35 |
Previous Close | 42.38 |
Day's Range | 42.11 - 42.38 |
52-Week Range | 19.59 - 43.59 |
Beta | 1.50 |
Analysts | Hold |
Price Target | 40.36 (-4.52%) |
Earnings Date | May 1, 2024 |
About CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selectiv... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CERE stock is "Hold." The 12-month stock price forecast is $40.36, which is a decrease of -4.52% from the latest price.
News
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in...
CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeu...
AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio
Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say
AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks...
Cramer reacts to AbbVie buying Cerevel Therapeutics
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to...
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
CNBC's David Faber delivers his latest Faber Report.
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout
U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals...
Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie
MILWAUKEE , Dec. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click her...
CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics
NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, In...
Cerevel options trading surge before AbbVie deal news raises eyebrows
Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer...
AbbVie to buy drug developer Cerevel for $8.7 billion
AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Hum...
AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal
AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's “robust” neuroscience pipeline adds medications that may transform stand...
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline...
Exclusive: AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources
AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc , a developer of drugs for neurological conditions such as Parkinson's, people familiar with the mat...
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson's Disease
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease
Cerevel Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced th...
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track...
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, ann...
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, ann...
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that me...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE). Such investo...
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash...
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...